Alergia e Imunologia

[Preprint] Estudo randomizado | Reforço vacinal com vacina heteróloga vs. homóloga em pacientes imunossuprimidos sem soroconversão de anticorpo contra SARS-CoV-2 após vacinação primária com vacina de mRNA.

12 Set, 2021 | 20:55h

Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial – medRxiv

Comentário no Twitter (fio – clique para saber mais)

Results of 60-person randomized trial of 3rd shot of mRNA or AZ vax in people on rituximab who didn't seroconvert after BNT-Pfizer (most) or Moderna vax. Found dose 3 reduced those with no humoral or cellular response from 31% to 6% …1/2 https://t.co/HIjeDaFy7w Preprint #IC

— Hilda Bastian, PhD (@hildabast) September 8, 2021

Crianças e COVID: por que sistemas imunológicos jovens ainda estão no topo.

8 Set, 2021 | 15:20h

Kids and COVID: why young immune systems are still on top – Nature

[Preprint] M-A de 12.001.447 indivíduos mostra que os previamente infectados com SARS-CoV-2 tiveram uma redução de 81% na chance de reinfecção.

8 Set, 2021 | 15:13h

The prevalence of adaptive immunity to COVID-19 and reinfection after recovery, a comprehensive systematic review and meta-analysis of 12 011 447 individuals – medRxiv

Comentário no Twitter

A new systematic review of over 12 million people from 54 studies at up to 8 months following Covid. >90% prevalence of IgG antibodies, reinfection 0.2% (an 81% risk reduction) https://t.co/ljir4DV1zU ("did not examine evidence for immunity against the new variants") pic.twitter.com/pT7A2KA9FV

— Eric Topol (@EricTopol) September 7, 2021

Intervalos maiores entre as doses e doses de reforço da vacina da AstraZeneca estão associados com aumento da imunogenicidade.

7 Set, 2021 | 22:13h

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) – The Lancet

Comentário convidado: Longer intervals and extra doses of ChAdOx1 nCoV-19 vaccine

Comentários no Twitter

(fio – clique para saber mais)

Substudy suggests extended interval (up to 45 wks) before 2nd dose of ChAdOx1 nCoV-19 leads to increased antibody titres, offering more flexibility in vaccine schedules.

Extended interval before 3rd dose resulted in further increase in immune responses. https://t.co/J3xOwSSYMN pic.twitter.com/8GotDI4ctS

— The Lancet (@TheLancet) September 2, 2021

(fio – clique para saber mais)

New @TheLancet
The heightened immune response to longer spacing @AstraZeneca 1st -> 2nd vaccine doses and the response 3rd booster dose, with high neutralizing antibodies and T cellshttps://t.co/A2UcPVIFYP pic.twitter.com/zfYaW0T8Yf

— Eric Topol (@EricTopol) September 1, 2021

Opinião | Vídeo: imunidade é o único caminho para atravessar uma pandemia (com Dra. Monica Gandhi).

7 Set, 2021 | 22:04h

Immunity Is The Only Way Through A Pandemic (w/Dr. Monica Gandhi) – ZDoggMD

Agência da União Europeia afirma que o foco deve ser sobre a oferta de vacinação inicial para todos, e não sobre as doses de reforço.

3 Set, 2021 | 12:50h

EU agency says to focus on vaccines first not booster shots – Associated Press

Ver também: European officials say COVID-19 booster isn’t urgent – CIDRAP

Estudo randomizado | Em pacientes com trombocitopenia imune, a adição de micofenolato mofetil ao regime padrão de glicocorticoide reduziu a doença refratária ou reincidente, mas esteve associada com diminuição na qualidade de vida relacionada à função física e à fadiga.

3 Set, 2021 | 12:42h

Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia – New England Journal of Medicine

Revisão | COVID-19 e doenças inflamatórias imunomediadas: efeitos da doença e do tratamento sobre os desfechos de COVID-19 e as respostas vacinais.

3 Set, 2021 | 11:17h

COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses – The Lancet Rheumatology

Comentário no Twitter

NEW REVIEW—COVID-19 and immune-mediated inflammatory diseases

Filippo Fagni and colleagues @UniFAU review the effect of disease and treatment on #COVID19 outcomes and #vaccine responseshttps://t.co/ue8XnDF1sM #LancetRheumatology @KorayTascilar pic.twitter.com/Yrk4SmeSbE

— The Lancet Rheumatology (@TheLancetRheum) August 27, 2021

Outro estudo mostra redução da imunidade conferida pela vacina de mRNA da Pfizer ao longo do tempo.

3 Set, 2021 | 11:16h

Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar – medRxiv

Conteúdos relacionados:

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

Studies: COVID vaccine protection waning against infection but not hospitalization.

Pfizer says it’s time for a Covid booster; FDA and CDC say not so fast.

Comentário no Twitter (fio – clique para saber mais)

The evidence of mRNA vaccine effectiveness (VE) waning grows: large Qatar experience shows substantial 5 month attrition for symptomatic infection VE below 50% and, to a lesser extent, vs hospitalization and deathhttps://t.co/4lIG68Bxm0 pic.twitter.com/rnyo0Si3RP

— Eric Topol (@EricTopol) August 27, 2021

[Preprint] Dose de proteção e reforço da vacina da Pfizer: um estudo nacional de Israel – “Doze dias ou mais depois da dose de reforço, observou-se uma redução de 11,4 vezes no risco relativo de infecção confirmada e redução acima de 10 vezes no risco relativo de doença grave.

2 Set, 2021 | 11:51h

BNT162b2 vaccine booster dose protection: A nationwide study from Israel – medRxiv